Sodium nitroprusside treatment for psychotic symptoms and cognitive deficits of schizophrenia: A randomized, double-blind, placebo-controlled trial
Sodium nitroprusside treatment for psychotic symptoms and cognitive deficits of schizophrenia: A randomized, double-blind, placebo-controlled trial
复制标题
硝普钠治疗精神分裂症的精神病症状和认知缺陷：一项随机、双盲、安慰剂对照试验
DOI：
10.1016/j.psychres.2018.08.079
复制
发表时间：
2018-11-01
影响因子：
11.3
通讯作者：
Lv, Luxian
中科院分区：
文献类型：
--
作者：
Wang, Xiujuan;Zhao, Jingyuan;Lv, Luxian
精神分裂症呈现出广泛的阴性、阳性和认知症状，综合治疗仍然是一个挑战。硝普钠（SNP）可迅速减轻精神分裂症患者的精神病性症状，改善认知功能，为治疗提供了一个新的可能方向。在本研究中，我们测试了SNP是否可以改善具有较长病史的精神分裂症患者的精神病性症状和认知功能。这是一项在2016年5月至2017年4月期间进行的随机、双盲、安慰剂对照试验。选择河南省精神病院精神分裂症患者42例，年龄18-45岁。采用阳性和阴性症状量表（PANSS）测量基线精神症状，采用韦氏成人智力量表测量基线认知功能。患者每隔一周接受两次SNP或安慰剂输注（每分钟0.5 μ g/kg，持续4小时）。在第一次和第二次输注后不久以及第二次输注后4周，我们使用相同的测试重新评估了精神症状和认知功能。我们没有发现SNP对精神病症状或认知功能的任何显著影响，尽管SNP相对耐受良好，具有良好的安全性。
Schizophrenia presents with a broad range of negative, positive, and cognitive symptoms, and comprehensive treatment is still a challenge. Sodium nitroprusside (SNP) has been reported to rapidly reduce psychotic symptoms and improve cognitive functions in patients with schizophrenia, providing a new possible direction for treatment. In this study, we tested whether SNP can improve psychotic symptoms and cognitive function in schizophrenia patients with longer disease history. This was a randomized, double-blind, placebo-controlled trial conducted between May 2016 and April 2017. Forty-two schizophrenia patients aged 18-45 years were recruited from Henan Province Mental Hospital. Baseline psychiatric symptoms were measured using the Positive and Negative Syndrome Scale (PANSS), and baseline cognitive functions were measured using the Wechsler Adult Intelligence Scale. Patients received two SNP or placebo infusions (0.5 mu g/kg per min for 4 h) at a one-week interval. We reassessed psychiatric symptoms and cognitive functions using the same tests shortly after the first and second infusions and 4 weeks after the second infusion. We did not find any significant effect of SNP over placebo on psychotic symptoms or cognitive functions, although SNP was relatively well tolerated with a good safety profile.